Exjade Gains Approval in EU

September 1, 2006
Oncology NEWS International, Oncology NEWS International Vol 15 No 9, Volume 15, Issue 9

The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

BASEL, Switzerland—The European Commission (EC) has granted approval for Novartis' Exjade (deferasirox) to treat patients with transfusional iron overload in all 25 member states of the European Union (EU). Exjade, available in the United States, is an oral iron chelator that provides continuous chelation coverage with a single daily dose.

Related Content:

Palliative and Supportive CareOncology NEWS International Vol 15 No 9
Guidelines for Palliative Treatment of Spinal Metastases: Choosing Between Stereotactic Body Radiation Therapy and Conventional Fractionation
Oncology Peer Review On-The-Go: Guidelines for Palliative Treatment of Spinal Metastases
Mindfulness-Based Intervention May Improve QOL in Patients with Breast Cancer